Dermatitis : contact, atopic, occupational, drug最新文献

{"title":"Allergic Contact Dermatitis® to Petrolatum: A Timeless Problem.","authors":"Monica Corazza, Martina Catani, Flavio Antonio Franchina, Alberto Cavazzini, Anna Bianchi, Alessandro Borghi, Lucrezia Pacetti, Natale Schettini","doi":"10.1089/derm.2024.0009","DOIUrl":"10.1089/derm.2024.0009","url":null,"abstract":"","PeriodicalId":93974,"journal":{"name":"Dermatitis : contact, atopic, occupational, drug","volume":" ","pages":"657-659"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140051313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Occupational Contact Dermatitis in Firefighters.","authors":"Daniela Baboun, Georgia Biazus Soares, Raymond Ezzat, Nicole Vecin, Marita Yaghi, Alberto J Caban-Martinez, Jonette Keri","doi":"10.1089/derm.2023.0269","DOIUrl":"10.1089/derm.2023.0269","url":null,"abstract":"<p><p><u><i></i></u> Occupational contact dermatitis (OCD) emerges as a salient concern within the context of firefighters, a professional cohort routinely exposed to an array of hazardous substances as an intrinsic facet of their occupational responsibilities. This continual skin exposure to a spectrum of allergenic and irritant agents engenders an elevated predisposition to OCD among firefighters. Notably, the ramifications of OCD in the domain of occupational health assume substantial import, contributing significantly to the prevalence of work-related dermatological maladies and consequential productivity decrements. However, it is conspicuous that the extant body of scholarly literature addressing the specific incidence of OCD in the firefighter demographic remains limited. To address this knowledge gap, we undertake a comprehensive inquiry into the phenomenon of OCD within the firefighter population. Our framework systematically classifies OCD into 3 discrete categories: allergic contact dermatitis, irritant contact dermatitis, and contact urticaria. Within each of these categories, we explore the various etiologies. Furthermore, our review highlights the multifaceted nature of OCD in firefighters and offers valuable insights into tailored preventive measures to mitigate its occurrence within these essential frontline workers. Our aim is to offer a comprehensive perspective on this occupational health issue and provide firefighters with practical strategies to protect their skin health while they continue their vital work in safeguarding our communities.</p>","PeriodicalId":93974,"journal":{"name":"Dermatitis : contact, atopic, occupational, drug","volume":"35 6","pages":"550-553"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142717939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Insulin Allergy Presenting as Protein Contact Dermatitis®: Letter.","authors":"Brittany Ehlert, Kathleen Coerdt, James S Taylor, Fred Hsieh, John S Anthony","doi":"10.1089/derm.2023.0249","DOIUrl":"10.1089/derm.2023.0249","url":null,"abstract":"","PeriodicalId":93974,"journal":{"name":"Dermatitis : contact, atopic, occupational, drug","volume":" ","pages":"674-675"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140178275","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Angiosarcoma Mimicking Allergic Contact Dermatitis® and Response to Timolol.","authors":"Tenzin Serpolamatsang, Kimberly Arrington, Samantha Gardeen, Joseph A Scherman","doi":"10.1089/derm.2023.0129","DOIUrl":"10.1089/derm.2023.0129","url":null,"abstract":"","PeriodicalId":93974,"journal":{"name":"Dermatitis : contact, atopic, occupational, drug","volume":" ","pages":"647-649"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140857667","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Suture-Induced Allergic Contact Dermatitis® to Polypropylene.","authors":"Helena Pires Pereira, Eduardo Silva, João Cardoso Lopes, Joni Costa Carvalho, Ana Todo-Bom","doi":"10.1089/derm.2024.0061","DOIUrl":"10.1089/derm.2024.0061","url":null,"abstract":"","PeriodicalId":93974,"journal":{"name":"Dermatitis : contact, atopic, occupational, drug","volume":" ","pages":"649-651"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140868876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Therapeutic Modulation of Dupilumab in Patients with Severe Atopic Dermatitis®: Clinical Effectiveness in Real Life.","authors":"Luca Mastorino, Richard Borrelli, Nicole Macagno, Federica Gelato, Erica Baima, Irene Richiardi, Giovanni Cavaliere, Pietro Quaglino, Michela Ortoncelli, Simone Ribero","doi":"10.1089/derm.2024.0146","DOIUrl":"10.1089/derm.2024.0146","url":null,"abstract":"<p><p><u><b><i></i></b></u> <u><b><i>Background:</i></b></u> De-escalation strategies have become increasingly used in the treatment of atopic Dermatitis® (AD) patients with dupilumab. Dose spacing (DS) refers to dose reduction by dosage elongation strategies from 2 to 8 weeks between dupilumab injections, in patients with stable response to treatment or affected by numerous adverse events. <u><b><i>Objectives:</i></b></u> Investigate safety and clinical effectiveness of DS strategy in AD patients treated with dupilumab. <u><b><i>Methods:</i></b></u> A retrospective cohort study was conducted on AD patients aged ≥18 years treated with dupilumab undergoing DS. Pre-post analyses were conducted on this cohort, termed cohort A, between effectiveness outcomes at baseline, at 16 weeks of treatment, at the index date identified as the mean follow-up time between dupilumab initiation and DS, and at subsequent two follow-up visits: T1 and T2. Based on the index date, a cohort B of AD patients on dupilumab treatment not experiencing DS was then compared with cohort A for the same outcomes at the same time points. <u><b><i>Results:</i></b></u> Seventy-three out of 452 patients treated with dupilumab underwent DS. The mean time since treatment initiation was 28.6 months. Mean Eczema Area Severity Index (EASI) from the index date remained stable until the second follow-up visit (T2) 0.2-0.8 with no significant pre-post differences (<i>P</i> > 0.05). Similar considerations can be made for mean number rating scale worst pruritus (NRSp), numerical rating scale disturbs of sleeping/sleeping disturb (NRSsd), mean Dermatology Life Quality Index (DLQI), and EASI Head and Neck. Attainment of relative outcomes remained stable for EASI75, 90, ≤ 7, DLQI ≤ 5, and NRSp ≤ 4. When compared with cohort B, no clinically significant differences were observed in mean reductions in all outcomes analyzed. <u><b><i>Conclusions:</i></b></u> DS in our study appears to be an effective and safe strategy in treating patients with severe AD after the initial therapeutic response.</p>","PeriodicalId":93974,"journal":{"name":"Dermatitis : contact, atopic, occupational, drug","volume":" ","pages":"625-635"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141750094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of Ingredients, Safety Hazards, and Marketing Claims of Popular Insect Repellents.","authors":"Caitlyn B Dagenet, Swetha Atluri, Lauren Gawey, Khiem A Tran, Jonathan Rick, Jay Kincannon, Jennifer L Hsiao, Vivian Y Shi","doi":"10.1089/derm.2023.0422","DOIUrl":"10.1089/derm.2023.0422","url":null,"abstract":"","PeriodicalId":93974,"journal":{"name":"Dermatitis : contact, atopic, occupational, drug","volume":" ","pages":"653-654"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142304525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy, Safety, and Early Relapse After Cessation of Upadacitinib Versus Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis®: A Real-World Study in China.","authors":"Jiling Zhu, Hanwen Wu, Yahui Ye, Qiuyang Xu, Junyi Shao, Zicheng Bai, Yiwen Zhou, Zhenyan Li, Jingjing Liu, Zhiming Li","doi":"10.1089/derm.2024.0014","DOIUrl":"10.1089/derm.2024.0014","url":null,"abstract":"<p><p><u><b><i></i></b></u> <u><b><i>Background:</i></b></u> The efficacy and safety of upadacitinib and dupilumab for atopic Dermatitis® (AD) in adolescent patients have been proven in clinical trials. However, few daily practice studies comparing agents have been conducted in this patient population. <u><b><i>Objectives:</i></b></u> This single-center retrospective cohort study aimed to investigate the efficacy, safety, and early relapse after cessation of upadacitinib and dupilumab for moderate-to-severe AD in Chinese adolescents. <u><b><i>Methods:</i></b></u> A retrospective study collected data on a cohort of 83 adolescent patients receiving upadacitinib or dupilumab from October 2021 to October 2023. This study comprised two main emphases. The first main emphasis involved the treatment phase, where the efficacy and safety of the two treatments were evaluated. Primary endpoints included the proportion of patients achieving an improvement of ≥50%, ≥75%, and ≥90% in Eczema Area and Severity Index (EASI) from baseline (EASI-50, EASI-75, EASI-90) and the proportion of patients achieving Validated Investigator Global Assessment (vIGA) 0/1 at week 4 and week 40. In the second main emphasis, AD recurrence after treatment discontinuation was assessed in the two treatment groups. The median time to relapse was calculated. <u><b><i>Results:</i></b></u> A total of 83 patients were enrolled. At week 4, the proportion of patients achieving the primary endpoints, including EASI-75 and EASI-90, was substantially higher with upadacitinib than with dupilumab (51.5% vs 14.0% [<i>P</i> < 0.001], 18.2% vs 2.0% [<i>P</i> < 0.05]). However, at week 40, higher proportion of patients on dupilumab were reaching EASI-50 and EASI-75 and vIGA 0/1. After the discontinuation of dupilumab or upadacitinib therapy, the Kaplan-Meier survival curve showed that the median time to relapse was 270 days in the dupilumab group and 18 days in the upadacitinib group. <u><b><i>Conclusions:</i></b></u> This study demonstrated that upadacitinib has superior short-term efficacy over dupilumab in adolescents with moderate-to-severe AD, whereas dupilumab trends toward better long-term remission over upadacitinib under the condition of treatment discontinuation in some patients.</p>","PeriodicalId":93974,"journal":{"name":"Dermatitis : contact, atopic, occupational, drug","volume":" ","pages":"636-645"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142010100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characterization of Pediatric Patch Testing: A Retrospective Review, 2020-2023.","authors":"Caroline Brumley, Puneet Arora, Sara A Hylwa","doi":"10.1089/derm.2024.0005","DOIUrl":"10.1089/derm.2024.0005","url":null,"abstract":"<p><p><u><b><i>Background:</i></b></u> Recent evidence shows similar rates of allergic contact Dermatitis® (ACD) among children and adults despite children accounting for less than 10% of patch testing subjects. With a need for in-depth analyses of pediatric ACD, we herein characterize a pediatric cohort at a large North American patch testing center. <u><b><i>Methods:</i></b></u> A retrospective chart review was conducted for 135 patients ages 1-17 years who underwent patch testing from July 2020 from August 2023. Data were stratified by age 1-5, 6-11, and 12-17 years. Significance-Prevalence Index Numbers (SPIN) were calculated. <u><b><i>Results:</i></b></u> A total of 86% were sensitized, 40% had a relevant reaction, and positivity rates were equal between males and females. Top allergens by SPIN differed with age, but overall were linalool hydroperoxides (SPIN = 11.01), propylene glycol (10.30), limonene hydroperoxides (10.27), fragrance mix I (5.62), and lanolin (4.90). In total, 14% of the top allergens were not represented on the North American Contact Dermatitis® Group standard series. Of those tested to personal products, 45% had positive reactions and 72% of which were relevant. <u><b><i>Conclusions:</i></b></u> Emulsifiers and fragrances were the most relevant allergen categories, with the impact of emulsifiers not previously reported. ACD may affect males and females equally in this population. Supplemental allergens and personal products tested \"as-is\" contribute to conclusive pediatric patch testing.</p>","PeriodicalId":93974,"journal":{"name":"Dermatitis : contact, atopic, occupational, drug","volume":" ","pages":"618-624"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141443970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient-Reported Association Between COVID-19 Infection or Vaccination and Onset of Allergic Contact Dermatitis®.","authors":"Nicholas Battis, Samuel F Ekstein, Eric Eugene Paul Cosky, Anne B Neeley","doi":"10.1089/derm.2023.0379","DOIUrl":"10.1089/derm.2023.0379","url":null,"abstract":"<p><p><u><b><i>Background:</i></b></u> Over the course of the COVID-19 pandemic, our clinic has encountered numerous patients who report that either COVID-19 vaccination or infection was the precipitating event for their development of allergic contact Dermatitis® (ACD). Up to this time, there is no formal investigation regarding COVID-19 vaccination or infection causing ACD. However, there have been several registry-based case series of associated dermatoses after COVID-19 infection or vaccination. <u><b><i>Objective:</i></b></u> This study aimed to describe patient-reported associations between COVID-19 infection or vaccination and onset of ACD. <u><b><i>Methods:</i></b></u> A single-center retrospective noncomparative chart review of 1073 patients patch tested at the Park Nicollet Contact Dermatitis® Clinic (Minneapolis, MN) from March 1, 2020, to March 1, 2022, was performed. <u><b><i>Results:</i></b></u> Of 1073 patients included in our study, 5 patients (0.47%) reported ACD symptom onset after COVID-19 infection and 12 patients (1.11%) reported onset after COVID-19 vaccination. Rates of clinical relevance were not significantly different than the general population for those who attributed ACD to COVID-19 infection or vaccination. <u><b><i>Conclusions:</i></b></u> To our knowledge, this is the first study in the literature investigating the potential association between COVID-19 vaccination or infection and the development of ACD through extensive retrospective chart review.</p>","PeriodicalId":93974,"journal":{"name":"Dermatitis : contact, atopic, occupational, drug","volume":" ","pages":"614-617"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140295649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}